PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Cash & equivalents declining -27.41% while AGEN's grows 198.39%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Below half of AGEN's 198.39%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Other current assets growth < half of AGEN's 23.75%. David Dodd sees a leaner approach to short-term items.
-28.37%
Below half of AGEN's 139.44%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
1187.39%
≥ 1.5x AGEN's 23.58%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of AGEN's -0.03%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
≥ 1.5x AGEN's 8.47%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
Below half of AGEN's 80.30%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.53%
1.25-1.5x AGEN's -6.53%. Martin Whitman sees potential reliance on supplier financing. Verify liquidity.
-29.62%
Less than half of AGEN's 9158.22%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Below half of AGEN's 1401.53%. Michael Burry suspects a big gap in pre-sales traction.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Less than half of AGEN's 55.02%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x AGEN's 6.93%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Similar yoy to AGEN's 17.45%. Walter Schloss sees parallel expansions in total liabilities.
2.97%
Less than half of AGEN's 11.84%. David Dodd sees fewer share issuances vs. competitor.
-3.03%
Below half AGEN's 1.57%. Michael Burry suspects major net losses or high dividends vs. competitor.
25.83%
Less than half of AGEN's -44.28%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
Below half AGEN's 32.66%. Michael Burry sees potential underperformance in building shareholder capital.
-17.83%
Below half AGEN's 80.30%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Above 1.5x AGEN's 56.17%. Michael Burry sees a major jump. Investigate leverage rationale.
37.73%
Less than half of AGEN's -246.25%. David Dodd sees better deleveraging or stronger cash buildup than competitor.